** Scientific tools maker Akoya Biosciences' AKYA.O shares fall 21.1% to $2.47 premarket
** On Thursday, co forecast 2024 rev. between $80 mln and $85 mln, lower than prior range of $96 mln to $104 mln
** Co makes products used by academics and biotechs to detect and map cell types and biomarkers, to help them understand patient response to therapy
** Since 2023, high interest rates have forced biotech companies, clients of life science firms, to cut spending
** Co posted Q3 sales of $18.8 mln, missing avg analysts' est. of $25.4 mln - LSEG
** As of last close, stock has fallen ~36% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.